$INBS Balance Sheet | Understand Stock

$INBS

$1.64 +$0.05 (3.14%) Close

$INBS Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q4 FY2026 As of Jun 30, 2026	Q3 FY2026 As of Mar 31, 2026	Q2 FY2026 As of Dec 31, 2025	Q1 FY2026 As of Sep 30, 2025	Q4 FY2025 As of Jun 30, 2025	Q3 FY2025 As of Mar 31, 2025	Q2 FY2025 As of Dec 31, 2024	Q1 FY2025 As of Sep 30, 2024	Q4 FY2024 As of Jun 30, 2024	Q3 FY2024 As of Mar 31, 2024	Q2 FY2024 As of Dec 31, 2023	Q1 FY2024 As of Sep 30, 2023	Q4 FY2023 As of Jun 30, 2023	Q3 FY2023 As of Mar 31, 2023	Q2 FY2023 As of Dec 31, 2022	Q1 FY2023 As of Sep 30, 2022	Q4 FY2022 As of Jun 30, 2022	Q3 FY2022 As of Mar 31, 2022	Q2 FY2022 As of Dec 31, 2021	Q1 FY2022 As of Sep 30, 2021
ASSETS
Current assets
Cash and cash equivalents
Accounts receivable, net
Subscription receivable from shareholders, net
Inventories, net
Grant receivable, current portion
Research and development tax incentive receivable
Deferred charges
Assets held for sale
Prepaid expenses and other current assets
Total current assets

Property and equipment, net
Other non-current assets
Finance lease right-of-use assets
Goodwill
Operating lease right-of-use assets
Intangibles, net
Long-term grant receivable

Capital work in progress
Total assets
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities
Accounts payable and accrued expenses
Current portion of deferred grant income
Current portion of finance lease liabilities
Current portion of operating lease liabilities
Deferred grant income
Current employee benefit liabilities
Notes payable
Total current liabilities

Employee benefit liabilities
Employee benefit liabilities, less current portion
Finance lease liabilities
Operating lease liabilities, less current portion
Long-term deferred grant income
Notes payable, less current portion
Convertible notes payable
Total liabilities
Shareholders’ equity
Preferred stock value
Series C Preferred Stock
Series D Preferred Stock
Common stock, $0.01 par value, 100,000,000 shares authorized, 2,905,615 and 2,905,603 shares issued and outstanding, as of June 30, 2026, respectively; 732,339 and 732,327 shares issued and outstanding, as of June 30, 2025, respectively
Treasury stock, at cost, 12 shares as of June 30, 2026 and 2025, respectively
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive loss
Total consolidated Intelligent Bio Solutions Inc. equity
Non-controlling interest
Total shareholders’ equity

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

Comments